To Investigate JAK2V617F Mutation In Patients With One Or More Lines Blood Cells Proliferation And Analysis Of Its Clinical Significance

Objective:To investigate JAK2 V617F mutation in patients with one or more lines blood cells proliferation who were highly suspect MPDs in clinical and analysis of its clinical significance,which could elevate the level of diagnosis in MPDs patients.Method:A study is on 140 patients with one or more lines blood cells proliferation who were treatment in the First Affiliated Hospital,College of Medicine,Zhejiang University during June in 2007 to March in 2009.Allele-specific PCR(AS-PCR) was applied to identify JAK2V617F mutation,then we analyzed the incidence of the JAK2V617F mutation and explore the correlation between the JAK2 V617F point mutation and the clinical diagnosis in patients with one or more lines blood cells proliferation who were highly suspect MPDs in clinical.Results:JAK2V617F point mutation was detected in 71/140(49.3%) patients, including 33/49(67.3%) erythrocytosis patients,35/76(49.3%) thrombocytosis patients,1/15(6.7%) leukocytosis patients.In the erythrocytosis or thrombocytosis group,the absolute number of male patients was less than the female patients,but male patients with JAK2V617F mutation detection rate was signifycantly higher than female patients.The age of onset in each group was not statistically significant. Conclusion:1.The rate of JAK2V617F mutation in the clinical equivocal patients is lower than in the MPDs patients,so we should test the bone marrow routine,biopsy,blood plasma EPO level,and the other mutation to detect the reactive blood cells proliferation.2.The rate of JAK2V617F mutation is higher in the erythrocytosis and thrombocytosis patients,especially in the male patients,so it is sense to do this test.The rate is lower in the female patients,so that we could do more tests to detect the reactive blood cells proliferation3.The rate of JAK2V617F mutation is low in the leukocytosis patients,so we should test the bone marrow routine and BCR-ABL fusion gene first.